Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer

NCT ID: NCT01851174

Last Updated: 2018-02-07

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2015-01-31

Brief Summary

To determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.

Detailed Description

This study will help determine whether the occurrence of adverse events can be decreased by moving to a bi-weekly, opposed to a weekly, dosing schedule of gemcitabine plus nab-Pacitaxel for the treatment of unresectable/metastatic pancreatic cancer.

Conditions

Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Gemcitabine and nab-Paclitaxel

Gemcitabine (1,000 mg/m^2) administered intravenously on days 1 and 15, every 28 days

nab-Paclitaxel (125 mg/m^2) administered intravenously on days 1 and 15, every 28 days

Group Type: EXPERIMENTAL

Gemcitabine

Intervention Type: DRUG

Patients will receive Gemcitabine (1,000 mg/m\^2) IV over 30 minutes after nab-paclitaxel infusion

nab-Paclitaxel

Intervention Type: DRUG

Patients will receive nab-Paclitaxel (125 mg/m\^2) IV over 30 minutes before Gemcitabine infusion

Interventions

Gemcitabine

Patients will receive Gemcitabine (1,000 mg/m\^2) IV over 30 minutes after nab-paclitaxel infusion

Intervention Type: DRUG

nab-Paclitaxel

Patients will receive nab-Paclitaxel (125 mg/m\^2) IV over 30 minutes before Gemcitabine infusion

Intervention Type: DRUG

Other Intervention Names

Gemzar; Abraxane

Eligibility Criteria

Inclusion Criteria

1. Patients must have histologically-proven unresectable/metastatic pancreatic adenocarcinoma.

2. Patient has one or more radiographically measurable tumor.

3. Patients may have received prior adjuvant chemotherapy or radiation therapy (RT).

4. Age ≥ 18 years.

5. Patient must have read, understood, and provided written informed consent and HIPAA authorization after full explanation of the nature of the study.

6. ECOG performance status 0 - 2 and an expected survival of at least 3 months.

7. Acceptable hematological parameters within 2 weeks of commencing study therapy as follows:

• Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
• Platelet count ≥ 100 x 10^9/L
• Hemoglobin (Hgb) ≥ 9g/dl

8. Patients with adequate organ function as measured by:

A. Cardiac: American Heart Association Class I: Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.

B. Hepatic: Bilirubin ≤ 2.0 mg/ and ALT and AST ≤ 1.5x the upper limit of normal.

C. Renal: Creatinine ≤ 1.5 mg/dl and no other chronic kidney disease.

9. Women must meet one of the following criteria:

• Post-menopausal for at least one year
• Surgically incapable of child-bearing
• Utilizing a reliable form of contraception for the duration of study participation. Women of child-bearing potential must have a negative serum β-HCG within 7 days of study drug administration.

Exclusion Criteria

1. Previous use of nab-Paclitaxel for treatment of pancreatic cancer either as monotherapy or combination in neo-adjuvant, adjuvant, or the metastatic setting.

2. Previous use of any chemotherapy or radiation therapy for metastatic disease.

3. Patient has known brain metastases, unless previously treated and well-controlled for at least 3 months (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart).

4. Other significant active or chronic infection.

5. History of active other malignancy excluding basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia.

6. Pregnant or nursing females.

7. Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity.

8. Major surgery, other than diagnostic surgery within 4 weeks of study entry.

9. Patient requires a legal authorized representative for consenting.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Western Regional Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Madappa Kundranda, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Western Regional Medical Center

Locations

Western Regional Medical Center

Goodyear, Arizona, United States

Countries

United States

Other Identifiers

WRMC 12-25

Identifier Type: -

Identifier Source: org_study_id